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Background: Heterozygous loss of function mutations within the Filamin A gene in Xq28 are the most frequent
cause of bilateral neuronal periventricular nodular heterotopia (PVNH). Most affected females are reported to initially
present with difficult to treat seizures at variable age of onset. Psychomotor development and cognition may be
normal or mildly to moderately impaired. Distinct associated extracerebral findings have been observed and may
help to establish the diagnosis including patent ductus arteriosus Botalli, progressive dystrophic cardiac valve
disease and aortic dissection, chronic obstructive lung disease or chronic constipation. Genotype-phenotype
correlations could not yet be established.
Methods: Sanger sequencing and MLPA was performed for a large cohort of 47 patients with Filamin A associated
PVNH (age range 1 to 65 years). For 34 patients more detailed clinical information was available from a structured
questionnaire and medical charts on family history, development, epileptologic findings, neurological examination,
cognition and associated clinical findings. Available detailed cerebral MR imaging was assessed for 20 patients.
Results: Thirty-nine different FLNA mutations were observed, they are mainly truncating (37/39) and distributed
throughout the entire coding region. No obvious correlation between the number and extend of PVNH and the
severity of the individual clinical manifestation was observed. 10 of the mutation carriers so far are without seizures
at a median age of 19.7 years. 22 of 24 patients with available educational data were able to attend regular school
and obtain professional education according to age.
Conclusions: We report the clinical and mutation spectrum as well as MR imaging for a large cohort of 47 patients
with Filamin A associated PVNH including two adult males. Our data are reassuring in regard to psychomotor and
cognitive development, which is within normal range for the majority of patients. However, a concerning median
diagnostic latency of 17 to 20 years was noted between seizure onset and the genetic diagnosis, intensely delaying
appropriate medical surveillance for potentially life threatening cardiovascular complications as well as genetic risk
assessment and counseling prior to family planning for this X-linked dominant inherited disorder with high
perinatal lethality in hemizygous males.
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Neuronal heterotopia (NH) is one of the most frequent
malformations of cortical development observed in pa-
tients with epilepsy [1]. It is characterized by an ectopic
accumulation of neurons that fail to migrate to the cere-
bral cortex [2]. NH is a morphologically and etiologically
heterogeneous condition, in particular solitary nodules
may be observed as an unspecific finding either isolated
or with various complex brain malformations. The most
frequent symmetric manifestation of periventricular
nodular heterotopia (PVNH) is located along the walls
of both lateral ventricles predominantly in females and
results from heterozygous loss of function mutations in
the X-linked FLNA gene [3, 4]. It is associated with high
intrauterine and perinatal lethality in hemizygous males
presumably from excessive bleeding, however on rare
occasions boys and adult hemizygous male carriers of
FLNA mutations have been reported [4, 5]. The gene
product Filamin A is a large cytoplasmic actin-binding
and cross-linking protein of diverse functions including
initiation of cell migration and spreading, coagulation
and aspects of vessel wall integrity [6–8]. Cellular func-
tion of Filamin A is further modulated by dimerization
with the homologous protein Filamin B, which may res-
cue defective Filamin A depending upon the cellular en-
vironment [6]. Functional imaging indicates that the
FLNA associated ectopic cortical neurons are function-
ally integrated into motor circuits [9]. The phenotype in
females with heterozygous FLNA loss of function muta-
tion is very variable. Difficult to treat epileptic seizures
are the core clinical finding in about 90 % of the patients
and may only start in adulthood [3, 8, 10]. Additional
neurological findings are rather discrete and may include
deficits in reading, processing speed and executive func-
tions, only detectable in subtle neurocognitive testing in
about 80 % of patients [11]. Penetrance in heterozygous
FLNA mutation carriers is reduced and asymptomatic
PVNH may be detected through predictive carrier test-
ing or incidentally in cerebral MR imaging as the only
manifestation of a FLNA mutation.
Other rare genetic causes of PVNH include chromo-
somal imbalances and submicroscopic genomic copy
number variations (CNV) and rare mutations within the
ARFGEF2 gene resulting in autosomal recessive inher-
ited PVNH. ARFGEF2 encodes the brefeldin-inhibited
guanine exchange factor 2 (BIG2) protein [12]. BIG2
plays a key role in vesicle transport between the trans-
Golgi apparatus und the cell membrane. These children
are more severely affected and present with early onset
epilepsy, congenital microcephaly, severe mental retard-
ation and increased susceptibility to infections [13].
Cerebral MR imaging of FLNA-associated PVNH in
addition often reveals an enlarged pericerebellar cerebro-
spinal fluid space in the presence of normal cerebellarand 4th ventricle anatomy. This will be referred to as
“mega cisterna magna” [14].
Less frequent FLNA-associated extracerebral manifes-
tations include persistent ductus arteriosus Botalli in
the newborn, chronic obstipation, an Ehlers-Danlos-like
phenotype affecting connective tissues, cardiac valve dis-
ease as well as chronic obstructive lung disease and
OPD spectrum skeletal phenotypes (oto-palato-digital
syndrome) [15–20].
Small series of PVNH patients on electrophysiological,
radiological, histological findings and neurosurgical out-
come after epilepsy-surgery have been reported without
genetic data [1, 16]. Here we describe for the first time
the phenotypic spectrum of a genetically defined larger
patient cohort with FLNA mutations including neuroim-
aging, neurological and extracerebral findings.
Patients and methods
Patients
Samples of all patients were referred for genetic testing
of the FLNA gene by neuropediatricians, neurologists or
geneticists with informed consent of the patients and/or
their parents. For a subset of 34 patients clinical and an-
amnestic data were collected retrospectively using a struc-
tured, standardized questionnaire specifically designed
for patients with FLNA-associated PVNH or from clin-
ical charts, respectively (Table 1). The questionnaires
systematically asked for family history/miscarriages,
epilepsy/seizures, clinical findings on neurological exam-
ination, cognitive development and developmental
milestones as well as “associated clinical findings” (ACF)
as listed in Table 2. The questionnaires were processed by
the patients themselves together with their physicians
and/or caregivers. In 20 patients original MR images
were available for assessment. Clinical data from these
questionnaires as well as individual clinical charts from
the remaining patients were evaluated as available and
correlated with the obtained genetic results and findings
of MR imaging.
Mutation analysis
Genomic DNA was prepared from peripheral blood.
With informed consent the entire FLNA coding se-
quence and flanking splice sites (reference sequence
NM_001110556.1) were amplified by PCR and analyzed
for potential sequence variations by direct sequencing of
PCR products using an ABI Prism Big-Dye Terminator
Cycle Sequencing Kit version 1.1 and ABI 3100 DX
Avant sequencer; Applied Biosystems, Foster City, Calif.,
USA). Reaction protocols have previously been described
[5, 15, 16]. Larger FLNA exon deletions or duplications
were identified using the commercially available multi-
plex ligation dependent probe amplification (MLPA) kit
P-061 (MRC-Holland, Amsterdam, the Netherlands).
Table 1 Summary of the clinical and genetic data
Family/pat Age at genetic
diagnosis (years)
Clinical
subgroup
Associated clinical
findings (ACF)
cDNAsequencealteration Proteinchange Mutation type
1 16,9 4 2 c.120delG heterozygous p.Trp41GlyfsX17 Frameshift
2 34,3 3 c.289C>T heterozygous de novo
(both parents wildtype)
p.Pro97Ser Missense
3 22,1 c.464G>A heterozygous de novo p.Trp155* Nonsense
4 31,8 2 0 c.961G>T heterozygous p.Glu321* Nonsense
5 37,6 4 c.1065+1G>C heterozygous IVS7+1G>C ds Splice site mutation
6 25,4 3 1 c.1065+1G>T heterozygous IVS7+1G>T ds Splice site mutation
7 17,1 4 1 c.1087C>T heterozygous p.Gln363* Nonsense
8 41,4 2 0 c.1351_1352insAG heterozygous p.Gly452ArgfsX47 Frameshift
9 32,1 c.1580_1581insCAGAAGGACCTGGGGGATG
heterozygous
p.Arg527ProfsX100 Frameshift
10 57,0 c.2022+1G>A heterozygous IVS13+1G>A ds Splice site mutation
11 II/1 3,4 4 0 c.2192dupA heterozygous maternal p.Tyr731* Nonsense
I/1 31,9 3 0 c.2192dupA heterozygous de novo p.Tyr731* Nonsense
12 30,0 2 1 c.2565+2T>G heterozygous IVS17+2T>G ds Splice site mutation
13 19,0 c.2612dupA heterozygous de novo p.Asp871GlufsX4 Frameshift
14 17,9 1 1 c.2943_2944_ + 2delGAGT heterozygous
de novo
IVS20_-2_ + 2del ds Splice site mutation
15 II/1 33,3 c.2983_2987delTCAAA heterozygous
maternal
p.Ser995GlyfsX31 Frameshift
I/1 55,4 c.2983_2987delTCAAA heterozygous p.Ser995GlyfsX31 Frameshift
16 17,2 2 2 c.3174delT heterozygous p.Leu1059TrpfsX12 Frameshift
17 16,6 2 1 c.3742C>T heterozygous p.Gln1248* Nonsense
18 37,3 3 1 c.4294C>T heterozygous p.Gln1432* Nonsense
19 51,7 3 0 Deletion exon 25 heterozygous ? Exondeletion
20 1,7 c.4303+2T>G heterozygous IVS25+2T>G ds Splice site mutation
21 18,0 c.4576G>T heterozygous p.Gly1526* Nonsense
22 12,4 c.4720delG heterozygous de novo p.Asp1574ThrfsX39 Frameshift
23 II/1 33,0 2 0 c.4994dupA heterozygous maternal p.Ile1666AspfsX12 Frameshift
I/1 65,8 c.4994dupA heterozygous p.Ile1666AspfsX12 Frameshift
24a II/1a 30,7 1 0 c.5686G>A heterozygous paternal p.Gly1896Arg/Splice Splice site mutation
II/2a 28,9 3 1 c.5686G>A heterozygous paternal p.Gly1896Arg/Splice Splice site mutation
I/1 malea 62,2 2 0 c.5686G>A mosaicism p.Gly1896Arg/Splice Splicesitemutation
25 47,0 2 1 c.6321C>A heterozygous p.Cys2107* Nonsense
26 17,8 c.6898C>T heterozygous p.Gln2300* Nonsense
27 24,9 1 2 c.6908-2A>G heterozygous IVS42-2A>G Splice site mutation
28 2,5 4 2 c.6994_7003dupGCCCGCCGCC
heterozygous
p.Leu2335ArgfsX8 Frameshift
29 Male 38,2 2 3 c.7055_7070delCTTTTGCAGTCAGCCT
mosaicism
p.Ser2352* Nonsense
30 44,0 2 2 c.7075_7077delinsT heterozygous p.Gly2359CysfsX25 Frameshift
31 21,7 c.7115C>G heterozygous p.Ser2372* Nonsense
32 II/1 24,5 2 0 Heterozygous deletion exon 44 maternal Loss of function Exon deletion
II/2 24,1 2 0 Heterozygous deletion exon 44 maternal Loss of function Exon deletion
I/1 53,7 4 0 Heterozygous deletion exon 44 Loss of function Exon deletion
33 27,9 c.7223delG heterozygous de novo p.Gly2408AlafsX45 Frameshift
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Table 1 Summary of the clinical and genetic data (Continued)
34 1,0 4 2 c.7255C>T heterozygous p.Arg2419* de novo Nonsense
35 42,2 2 0 c.7533delC heterozygous p.Phe2512SerfsX24 Frameshift
36 7,9 4 1 c.7714G>A heterozygous; unclassified
variant
p.Val2572Ile - VUS3 Missense/splice
site mutation?
37 8,2 1 8 c.7840dupT heterozygous p.Tyr2614LeufsX136 Frameshift
38 II/1 16,5 4 1 Heterozygous deletion exons 40 to 3′UTR
maternal
Loss of function Exon deletion
I/1 41,5 4 0 Heterozygous deletion exons 40 to 3′UTR
de novo
Loss of function Exon deletion
39 31,3 3 2 Deletion exon 46 + duplication exons
4–22 de novo (both parents wildtype)
Loss of function Complex genomic
rearrangement
The two male patients are separately indicated in the family/patients row
afamily 24 has previously been published including detailed clinical data [5] and surgical correction of gastrointestinal dysfunction of patient 34 in [23]
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Mutation analysis
The patient cohort consists of 2 male and 45 female pa-
tients from 39 independent families with a median age
of 28.5 years at the time of genetic diagnosis (Table 1,
Fig. 1). For 14 families maternal samples were available
with additional paternal samples for 3 of them (families
2, 24 and 39) and results of parental carrier testing com-
patible with a de novo mutation for 10 index patients.
For 5 of the remaining index patients the carrier status
of their mothers or daughter (family 11) was only recog-
nized during family studies at an age between 16 and
65 years (median 44,1 years), where none of those carrierTable 2 Associated clinical findings (ACF) observed in 34 patients fr
n observed per group vs. total
Cardiovascular I II
Aortic valve insufficiency 1 4
Aortic dilation 1
Mitral valve insufficiency
Persistent ductus arteriosus 2 1
Cerebral aneurysm 1
Internal findings
Gastrointestinal dysfunction 1
Liability to hematoma 1
Obstructive lung disease 2
Dysmorphism/physical handicaps
Joint hypermobility 2 1
Musclular hypotonia 1
Talipes
Skin hyperextensible 1 1
Craniofacial dysmorphism 1 1
Associated clinical findings (ACFs) were documented in 19 of the patients (55.9 %)
However, in absolute numbers there were 12 ACFs in 4 patients in group I (average
group III (0.43/patient) and 10 in 10 patients in group IV (1,0/patient). The load of m
arteriosus Botalli (PDA) in 5 patients and cardiac valve disease in 8 patients were th
age or neurological phenotyperelatives so far had experienced seizures or other clinical
abnormalities previously associated with FLNA mutations.
Identified FLNA mutations are distributed through-
out the entire FLNA gene and include 37 truncating
mutations (frameshift: 13, nonsense: 12, splice site: 8;
exon deletions: 4). Missense variants were only identi-
fied in 2 patients. For one of these two missense variants
p.Pro97Ser (c.289C>T) the absence in both parental sam-
ples further suggests its functional and clinical relevance
as de novo mutation. It has not been annotated in LOVD3,
public HGMD or Ensemble or in other published pa-
tients or controls available to us. In close vicinity add-
itional pathogenic missense mutations p.Glu82Val andom our cohort
percentage
III IV Total (%)
3 8 (23.5)
1 (2.9)
1 1 (2.9)
2 1 6 (17.6)
1 2 (5.9)
1 2 (5.9)
1 2 (5.9)
2 (5.9)
2 5 (14.7)
1 (2.9)
1 1 (2.9)
2 (5.9)
1 3 (8.8)
3 per patient), 10 in 13 patients in group II (0.77/patient), 4 in 7 patients in
ultiple different ACFs seems to be higher in younger patients. Patent ductus
e most frequently observed ACFs, they showed no correlation to the patients’s
Fig. 1 a Patient age at onset of the seizure disorder (red) and at genetic diagnosis (blue) with diagnostic latency (black line); b schematic structure
of the corresponding Filamin A protein (not to scale) with the two NH2-terminal actin binding calponin homology domains (CHD1-2) and 24
immunoglobulin-like filamin repeat domains interrupted by two hinge regions (red triangles)
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the other patient with the missense variant p.Val2572Ile
no parental samples were available. It has been annotated
as rs377518545 and observed in heterozygous state in 2
out of 2332 females and none of the 1784 males from the
ESP6500 cohort of European Americans, nor in any
of the 3358 ESP6500 alleles of African American ori-
gin. Bioinformatic assessment suggested the activation of
a cryptic splice site. However, in the absence of parental
samples and clear evidence for functional and clinical rele-
vance we currently consider this as an unclassified variant.
For one adult male patient in this study (family 29) a
16 bp deletion in exon 44 was observed in high grade
mosaic state in the available blood sample with introduc-
tion of a stop codon directly at the mutation site
(p.Ser2352*; Fig. 2a). Based on the available chromato-
grams of the Sanger sequence at least 60 % of the FLNA
alleles in genomic DNA prepared from peripheral blood
were estimated to carry the 16 bp deletion. A normal
male karyotype 46,XY in lymphocytes from peripheral
blood was confirmed and in addition fluorescence in situ
hybridization among 100 further metaphases and inter-
phase nuclei did not reveal any cell with more than one
signal for the X chromosome, thus excluding clinicallyrelevant X gonosomal mosaicism for 47,XXY as an alter-
native explanation. His mutation was not present in a
blood sample of his mother, thus further confirming de
novo occurrence of this nonsense mutation during early
embryonal development.
The only other male patient of this study (# I/1 from
family 24) was also found to carry a potentially truncat-
ing FLNA splice site mutation c.5686G>A in mosaic
state estimated to affect 40 to 45 % of FLNA alleles in
peripheral blood, and was previously published [5].
Clinical findings
For 34 patients detailed clinical data were available (mean
age at genetic diagnosis: 28.5 years; range: 1 – 54 years):
data from standardized clinical questionnaires were
assessed from 24 patients. For further 10 patients clin-
ical data from medical records could be evaluated.
According to the age at first seizure patients were di-
vided into 4 clinical subgroups (Table 1):
Subgroup 1 seizure-onset in childhood
Four female patients were younger than 11 years at the
time of their first seizure (mean age 2.8 years; age range:
1–5 years). The causal FLNA mutation in this subgroup
Fig. 2 a High grade mosaic FLNA mutation c.7055_7070delCTTTTGCAGTCAGCCT in peripheral blood (upper sequence) of a 36 year old male
patient 29 with normal male karyotype 46,XY, resulting in the nonsense mutation p.Ser2352*, novel stop codon boxed. Wildtype sequence of the
healthy mother below. b–d cerebral MR imaging demonstrating extended PVNH bilaterally (b and c), diffuse white matter abnormalities and
inward rotated anterior ventricular horns (c), hypoplastic corpus callosum and large mega cisterna magna (d)
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3–28, Fig. 1). Three of these patients carried heterozygous
splice site mutations (patients # 14, 27 and II/1 from
family 24), for which specific consequences on the ab-
normal FLNA transcript and protein cannot be predicted.
The fourth of these female patients (# 37) is heterozygous
for the most C-terminal truncating mutation identified in
our cohort with abrogation of the regular stop codon,
elongated transcript and most severe complex phenotype
including severe and multi-organ connective tissue mani-
festation in the presence of moderate PVNH (Fig. 3).
Subgroup 2 seizure-onset during adolescence
In 13 clinically documented patients the first seizure oc-
curred during adolescence at a mean age of 15.5 years
(range 12–20). Diagnostic latency regarding mutation
detection in this subgroup was 18.3 years (range 1–47,
Fig. 1). Two of these patients were males with mosaic
truncating mutation detected in peripheral blood [5].
Subgroup 3 seizure-onset in adulthood
Only 7 of the clinically documented patients had their
first seizure beyond the age of 20 years (mean: 27.4;
range: 24–37) with an average latency for genetic diag-
nosis of 7.2 years (range 0–26).
Subgroup 4 no seizures
The fourth subgroup of 10 females had not experienced
any seizures at the time of genetic diagnosis (mean age
at genetic diagnosis: 19.7 years (range: 1–54 years). Allof these patients were neurologically normal, reasons
for extended neurological examination including MR
imaging and EEG were either unexplained recurrent
headache/migraine (3 patients) or other clinical features
(5 patients) and/or predictive carrier testing for a famil-
ial FLNA mutation (3 patients).
Psychomotor development and cognition
Early psychomotor milestones data were available for 21
patients. In 18 patients they were reached within normal
limits. A selectively retarded speech development was
reported for one patient from subgroup 2 (patient # 4).
A more pronounced early developmental delay has been
observed in two female patients of subgroup 1 (patient #
II/1 from family 24 and patient # 37) with a more com-
plex phenotype including connective tissue involvement.
Cognitive impairment was noted in 4 patients - predom-
inantly with seizure onset prior to the age of 20 years: in
subgroup 1 in two of four patients (50 %) and only one
patient each in subgroups 2 (7.7 %) and 4 (10.0 %).
Moreover, educational data were available for 24 pa-
tients: all but two of them were able to attend regular
school and obtain professional education according to
age. A more profound cognitive impairment is docu-
mented for only one female index patient (patient # II/1
from family 24) [5].
Neurological findings
The clinical neurological examination was normal in 33
of 34 patients, in only one patient from subgroup 1
Fig. 3 a-c cMR imaging of 11 year old female patient 37 with complex FLNA associated phenotype including severe connective tissue disorder
with gastrointestinal, cardiac and vascular manifestation, resulting from heterozygous C-terminal FLNA frameshift mutation c.7840dupT. a and b
extended cortexisodense PVNH bilaterally; (b) white matter abnormalities and (c) large mega cisterna magna
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hypotonia has been documented. 5 patients from 4 fam-
ilies reported recurrent headache or migraine.
Neuroimaging findings
MR imaging confirmed bilateral nodularly arranged, het-
erotopic gray matter with periventricular distribution in
all assessed patients. The extent of PVNH greatly dif-
fered amongst patients, as did the number of associated
imaging findings (AIF, Table 3). 14 patients showed ex-
tensive, bilateral, confluent heterotopic conglomerates of
neuronal tissue (Figs. 1b and 2a, b).
A mega cisterna magna was observed in 18 of 20 pa-
tients with available sagittal MR imaging (Figs. 1d, 2c
and 3c). More importantly, in 9 of 20 patients we noted
specifically deformed anterior horns of the lateral ventri-
cles with characteristic inward rotation (Figs. 1c and 3b),
which have not been described before by other groups.
Corpus callosum hypoplasia was recognized in 8 of 20
patients with predominant thinning of the splenium
(Figs. 2d and 4c). For none of the available MR scans con-
vincing dilated ventricles or hydrocephalus were observed.
However, focal anomalies of the cortical gyral pattern
could be seen in one patient (index patient from family
5 with unilateral focal occipital cortical dysplasia) and
white matter lesions in 9 of 20 patients (Figs. 2c and 3b).
Those white matter lesions were located subcortically in 8Table 3 Neuroimaging findings
Associated imaging findings (AIF): Secondary imaging findings:
- Mega cisterna magna (14/15) - Dilated ventricles (2/15)
- Deformation anterior horns lateral
ventricles (8/12)
- “Cortical thinning” (0/12)
- White matter lesions (7/12) - Intracranial aneurysms (0/12)
- Corpus callosum hypoplasia (6/15)
- Abnormal cortical gyration (1/12)patients (average age at genetic diagnosis: 26.4 years) and
periventricularly in only one 62 year-old patient and in
this instance may rather represent age-associated inciden-
tal findings.
In our cohort we did not observe a correlation be-
tween the extent of PVNH with the age of onset of sei-
zures or overall clinical severity.EEG findings
EEGs results were available from 20 patients, 15 had epi-
lepsy, 7 of those exhibited discharges in the scalp EEG,
in 7 the EEG was normal, in 1 it showed focal slowing
as the key finding.
In 5 patients from subgroup 4 (without epilepsy) with
available EEG there were either unspecific changes (n = 3;
average age 12.3 years), epileptic discharges (n = 1; EEG at
the age of 8 years) or normal recordings (n = 1, age 3.4)
were documented. MR scans were available for two pa-
tients with focal slowing from this subgroup 4 and con-
firmed moderate and severe PVNH, respectively as well as
severe PVNH in one patient with normal EEG.
In subgroup 1, 2 of 3 EEGs were normal whereas the
third EEG showed epileptic discharges. MRIs were avail-
able for 2 clinically severely affected patients of subgroup
1. One had a normal EEG despite of a seizure-onset at the
age of 5: the MRI revealed a more severe cerebral pheno-
type (patient # 37; Fig. 3). The other had epileptic dis-
charges in the EEG (patient # II/1, family 24).
In sugroup 2, three of 8 EEGs were normal, 4 showed
epileptic activity and one was unspecifically disturbed
(focal slowing). MRIs were obtainable for 6 patients: 3
with discharges in the EEG and 3 with a normal EEG.
In subgroup 3, two of four EEGs revealed discharges
and 2 were normal. Two MRIs were available: one pa-
tient with discharges and one with a normal EEG both
had moderate PVNH.
Fig. 4 a, b coronal cMR imaging of the anterior ventricular horns with normal configuration (a) in 27 year old female patient 39 with PVNH only
along the central and occipital parts of the lateral ventricular walls and (b) with the more frequently observed anterior heterotopia and abnormal
inward rotation in 16 year old patient 16. c Sagittal cMR imaging of 17 year old patient 26 with characteristically shortened hypoplastic corpus
callosum and large mega cisterna magna
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One or more miscarriages were reported for 6 of 39 fam-
ilies. In family 32 the mother of two affected twin sisters,
all with heterozygous deletion of exon 44, reported 3 add-
itional pregnancies with miscarriage around the 12th ges-
tational week, her mother also had one miscarriage and 3
further live births (one boy and 2 girls). Evaluation of
available questionnaires revealed 18 live born siblings
of mutation carriers without obvious gender distortion
(8 males, 10 females). However, for most of their
mothers mutation status was unknown. No instance of
a late miscarriage, stillbirth or induced abortion due to
fetal malformations was documented in our cohort.Dysmorphic findings and connective tissue manifestation
We specifically asked for dysmorphic features, cardiac
disease, skin and joints abnormalities as well as cerebral
artery aneurysm and stenosis (Table 2). Cerebral arerial
findings were present in two girls.
Patient # 34 presented with complete nonrotation of
the bowel, absence of gastrophrenic ligaments, and non-
fixation of the intestines requiring acute extensive ab-
dominal surgery due to a wandering spleen with torsion
and dislocation into the umbilical area associated with
an upside-down volvulus of the stomach at the age of
15 months [23].
The same patient developed progressive dilatation of
the aorta with a diameter of 33 mm at the level of the
aortic root and 27 mm at the level of the ascending aorta
with aortic regurgitation. At the age of 12 years the aor-
tic valve and the ascending aorta were replaced with a
21 mm composite graft and a Saint Jude Medical aortic
valve prosthesis. Additionally, cerebral Doppler studies
revealed turbulent flow in the internal cerebral arteries
bilaterally at the age of 7 years, MR angiography con-
firmed bilateral stenosis of the intradural internal cerebralarteries. The patient was placed on low dose aspirin, but
the stenosis showed a slight progression over 4 years.
Patient #37 presented with extreme intestinal pseu-
doobstruction leading to severe constipation in adoles-
cence [24]. Because of absent bowel movements despite
the use of laxative and retrograde enemas, a Malone
button was placed in the coecum for anterograde
flushes at the age of 11 years. Constipation relapsed,
and at the age of 14 years an ileostomy stoma was
placed and relieved the constipation. Biopsies of the as-
cending colon and the terminal ileum revealed a rela-
tively strong tunica muscularis mucosae and small focal
lesions of fibrosis in the submucosa of the colon with
normal ganglia cells in the myenteric plexus. In the
same patient, a small aneurysm of 1 mm diameter of
the anterior communicating artery was noted on MR
angiography with a 3 Tesla high resolution MRI scan-
ner at the age of 12 years and did not show progression
on subsequent control imaging over 3 years. For 5 pa-
tients joint laxity or hypermobility was documented.
Talipes were documented in patient # 36.
Dysmorphism was reported for 3 of 34 patients (8.8 %)
including retrognathia, hypertelorism or low-set ears
and one male patient (# 29) with more severe clinical
manifestation within the OPD spectrum including the
characteristic broad and flattened OPD I-like endpha-
langes of both feet.
Twelve of 34 patients were reported to be compro-
mised by cardiovascular disease with documented per-
sistent ductus arteriosus Botalli in 5 patients. Functionally
relevant aortic valve insufficiency was observed in 8 pa-
tients with additional mitral valve insufficiency grade I
in patient # 28 and progressive aortic dilatation in pa-
tient # 37.
The male patient # 29 developed a progressive ob-
structive lung disease with severely reduced vital cap-
acity of 1.76 l and a FEV1 of 0.88 l at the age of 38 years,
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ately considering lung transplantation.
Discussion
We present clinical, neuroimaging and mutation data of a
large cohort of 47 patients with periventricular nodular
heterotopia resulting from heterozygous or rare instances
of mosaic FLNA mutations in males [16]. Our data con-
firm a specific FLNA-associated PVNH phenotype on MR
imaging with bilateral, predominantly confluent nodular
heterotopias extending along the entire length of the lat-
eral walls of both lateral ventricles. Within our PVNH co-
hort we did not observe a correlation between PVNH
extent and seizure phenotype or overall clinical course.
Extensive and confluent PVNH in our cohort was not un-
common in asymptomatic FLNA mutation carriers or
those from subgroup 3 with normal development and
onset of seizures only in adulthood. Further functional
studies may allow new insights into important protein
domains and interaction partners critically contributing
to the diverse effects of distinct FLNA mutations [25].
FLNA-associated PVNH is X-linked dominant inher-
ited with a high risk of 50 % for male offspring to be se-
verely affected. Interestingly, in our cohort no instances
of stillbirths or late abortion were recorded, nor were
milder affected male siblings with clinical findings of the
FLNA phenotypic spectrum. This further strengthens
the previously proposed hypothesis that (I) most hemizy-
gous truncating FLNA mutations lead to predominantly
early abrogation of intrauterine development [22], as
might have been the case in the 3 miscarriages around
the 12th week of gestation of patient # I/1 from family
32. (II) Our data from this large cohort further confirm,
that FLNA-associated PVNH in liveborn males is rare
and may only be compatible with postnatal development
in the presence of critical amounts of correct functional
full length cDNA either due to hypomorphic alleles, in-
complete splice effects or somatic mosaicism for trun-
cating mutations functionally similar to the situation in
heterozygous female mutation carriers [4].
Early mutation detection is critical as it allows genetic
counseling for women with heterozygous truncating
FLNA mutations and her relatives prior to family plan-
ning, to non-directly discuss the mode of inheritance,
clinical course and the options of prenatal genetic test-
ing or even preimplantation genetic diagnosis in order
to significantly support informed decisions. However, in
19 patients of our cohort the genetic diagnosis was
established more than 10 years, for 11 of these even
more than 20 years after seizure onset, although MR im-
aging with characteristic PVNH for some of them has
been obtained for several years.
Furthermore, early recognition of mutation carriers is
also important for extended medical surveillance [19, 20]:in our cohort cardiac disease was recorded for almost
half of all patients. Persistent ductus arteriosus is com-
monly recognized in time and properly treated. How-
ever, dysplastic cardiac valve disease and less frequently
aortic dilatation may be asymptomatic but still pro-
gress, while patients could benefit from early recogni-
tion, surveillance and appropriate treatment. The high
proportion of cardiovascular manifestations in our co-
hort clearly underscores the importance of early and re-
peated cardiovascular surveillance, even in currently
asymptomatic mutation carriers.
More recently, progressive obstructive lung disease
has been documented as a rare clinical manifestation in
FLNA mutation carriers [17]. In our cohort we present
another male patient with mosaic truncating mutation
and severe impairment of pulmonary function within
his 4th decade. Medical workup should therefore also
include attention for clinical signs of impaired respira-
tory function.
While the predominant clinical manifestation is sei-
zures [4, 11], which in more than half of the FLNA mu-
tation carriers of our cohort developed in childhood or
adolescence other less common manifestations were
seen in our cohort including one patient each with with
talipes deformation of the feet or muscular hypotonia.
Our data further confirm the rare association of FLNA
mutations with serious pseudoobstruction, initially re-
ported by our group [20] and add the unusual finding of
a complex intestinal malformation and malrotation as
potentially more severe congenital gastrointestinal mani-
festation, requiring extensive abdominal surgery in those
2 patients during childhood [23]. In concordance with
earlier reports laxity of joints and skin was rather fre-
quent and also obstructive lung disease was seen as de-
scribed above.
We specifically assessed psychomotor and cognitive
development, which was normal for almost all PVNH
patients in our cohort. Almost all patients were re-
ported to be developed according to age, both regard-
ing their psychomotor and cognitive skills. Our data are
especially reassuring, as almost all patients could obtain
and complete normal school and professional education
according to age. Significantly delayed early development
appears to be not common and was only noted in two pa-
tients from subgroup 1 with more complex and severe
phenotype, requiring more intensive education in a school
for children with special needs. In one of these girls, re-
current hospitalization with subsequent long and repeated
miss-out times at school may be an important cofactor
preventing attendance of a regular school.
Conclusions
In summary, we here present genetic, clinical and neu-
roimaging data of a large genetically defined cohort of
Lange et al. Orphanet Journal of Rare Diseases  (2015) 10:134 Page 10 of 1147 patients with FLNA-associated PVNH. Based on
the combined data of previous reports and our results
we emphasize the importance of early cerebral im-
aging in females with a history of patent ductus arter-
iosus and seizures, regardless of their age of onset or
cognitive impairment.
Identification of the underlying FLNA mutation should
prompt inclusion in regular intensified medical care in
an epilepsy center as well as cardiovascular surveillance by
physicians familiar with the wide phenotypic spectrum of
FLNA mutation carriers. Asymptomatic FLNA mutation
carriers may have epileptic discharges, but there is cur-
rently no evidence, that they may benefit from antiepilep-
tic medication. FLNA-associated seizures may occur at
any age, onset during adolescence or in adulthood is not
uncommon. Antiepileptic medication is effective in redu-
cing seizure frequency, but about one third of the patients
may not be free of seizures even with multimodal medica-
tion protocols. Whether or not lamotrigine alone or in
combination with specific add-on compounds will turn
out to be most effective to control FLNA-associated sei-
zures, is currently addressed by our group in an ongoing
clinical study.
Our data on this largest currently published cohort
of FLNA mutation carriers with characteristic PVNH
on MR imaging confirm a preferentially normal cog-
nitive development or only mild impairment, which
should not prevent further genetic workup. A clear
genotype-phenotype correlation was not obvious in
our series. However, early seizure onset in childhood
may more likely be associated with additional cardio-
vascular, gastrointestinal and musculoskeletal manifes-
tations. Earlier genetic diagnosis of this X-linked
dominant inherited disorder during the process of
clinical workup of PVNH identified in neuroimaging
should be sought in order to offer non-directive gen-
etic counseling prior to childbearing to affected fe-
males as well as their close relatives. Genetic diagnosis
should also warrant a thorough, systematic, general
medical work-up to identify common and less fre-
quently observed clinical findings affecting connective
tissue, lung as well as cardiovascular or gastrointestinal
function and to organize a specialized interdisciplinary
medical care and surveillance to ultimately further im-
prove long term outcome and quality of life of the af-
fected patients and their families.
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